PofoliaPofolia ile paylaşıldı

CA A Cancer Journal for Clinicians· 2020Q1

Kanser İstatistikleri, 2020: Yavaşlayan İlerleme ve Değişen Eğilimler

Cancer statistics, 2020

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal

Kısa özet

2020'de ABD'de 1,8 milyon yeni kanser vakası ve 606 bin ölüm bekleniyor; genel ölüm oranları 1991'den bu yana %29 düşüş gösterse de, ilerleme meme ve kolorektal kanserlerde yavaşladı, prostat kanserinde durdu.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • ABD'de 2020 yılı için tahmini 1,8 milyon yeni kanser vakası ve 606 bin ölüm.
  • Genel kanser ölüm oranı 1991'den bu yana %29 azalarak tahmini 2,9 milyon hayat kurtardı.
  • Kadınlarda meme ve kolorektal kanserlerde ilerleme yavaşladı, prostat kanserinde ise durdu.
  • Akciğer kanseri ölüm oranları hızlandı ve 2016-2017 arasındaki genel ölüm oranındaki %2,2'lik düşüşe katkıda bulundu.
  • Melanom ölüm oranlarındaki dramatik düşüşler, metastatik hastalık için yeni tedavilerle ilişkilidir.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.

Yazarların özeti; kaynağından alınmıştır. CA A Cancer Journal for Clinicians, 2020 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: Ekonomi ve Ekonometri

Economics and EconometricsEconomics, Econometrics and Finance